Nabi Biopharmaceuticals Executive Officers Base Salary Approval (March 2005)
Nabi Biopharmaceuticals' Compensation Committee approved new base salary levels for its executive officers, effective April 2005. The agreement lists the names of the executives and their respective annual base salaries, as set under their employment agreements. This document formalizes the salary structure for key company leaders, including Thomas H. McLain, Richard G. Clark, Raafat E.F. Fahim, Henrik S. Rasmussen, Mark L. Smith, and H. LeRoux Jooste.
EXHIBIT 10.1
NABI BIOPHARMACEUTICALS
BASE SALARY LEVELS OF EXECUTIVE OFFICERS
In March 2005, the Compensation Committee of the Board of Directors approved the following base salary levels for the following executive officers of Nabi Biopharmaceuticals pursuant to the terms of their employment agreements:
| Name | Base Salary as of April 2005 | ||
| Thomas H. McLain | $ | 450,000 | |
| Richard G. Clark | $ | 245,000 | |
| Raafat E.F. Fahim, Ph.D. | $ | 290,000 | |
| Henrik S. Rasmussen, M.D., Ph.D. | $ | 290,000 | |
| Mark L. Smith | $ | 280,000 | |
| H. LeRoux Jooste | $ | 290,000 | |
